"SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia" by Kyriakie Sarafoglou

Selected Works of Samer Nakhle, MD, FACE

Article

SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia

Journal of the Endocrine Society (2019)

Kyriakie Sarafoglou, University of Minnesota
Ron Newfield, University of California, San Diego
Maria Vogiatzi, Children's Hospital of Philadelphia
Erik Imel, Indiana University – Purdue University Indianapolis
A. Odugbesan, North Atlanta Endocrinology & Diabetes PC, Lawrenceville, GA, United States
Ivy-Joan Madu, DIABETES ASSOCIATES MEDICAL GROUP, Diabetes Associates Medical Group, Orange, CA, United States
Samer Nakhle, Palm Medical Group, Las Vegas, NV, United States
Alexis Howerton, Spruce Biosciences, San Francisco, CA, United States
Michael Huang, Spruce Biosciences, San Francisco, CA, United States
Kelly Vandever, Spruce Biosciences, San Francisco, CA, United States
Rong Lin, Biostatistical Consulting, Inc, Lexington, MA, United States
Alyssa Wu-Zhang, Biomedical writing consultant, San Jose, CA, United States
Richard Auchus, University of Michigan

Link

Disciplines

Publication Date

April 15, 2019

DOI

10.1210/JS.2019-SUN-LB064

Citation Information

Kyriakie Sarafoglou, Ron Newfield, Maria Vogiatzi, Erik Imel, et al.. "SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia" Journal of the Endocrine Society Vol. 3 (2019)
Available at: http://works.bepress.com/samer-nakhle/13/